IGC Pharma Inc (IGC)
0.426
0.00 (0.00%)
USD |
NYAM |
Apr 26, 10:43
IGC Pharma Revenue (Quarterly): 0.204M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.204M |
| September 30, 2023 | 0.291M |
| June 30, 2023 | 0.555M |
| March 31, 2023 | 0.166M |
| December 31, 2022 | 0.332M |
| September 30, 2022 | 0.202M |
| June 30, 2022 | 0.212M |
| March 31, 2022 | 0.122M |
| December 31, 2021 | 0.142M |
| September 30, 2021 | 0.056M |
| June 30, 2021 | 0.077M |
| March 31, 2021 | 0.081M |
| December 31, 2020 | 0.108M |
| September 30, 2020 | 0.125M |
| June 30, 2020 | 0.584M |
| March 31, 2020 | 0.029M |
| December 31, 2019 | 0.573M |
| September 30, 2019 | 1.821M |
| June 30, 2019 | 1.649M |
| March 31, 2019 | 1.542M |
| December 31, 2018 | 1.285M |
| September 30, 2018 | 0.811M |
| June 30, 2018 | 1.478M |
| March 31, 2018 | 1.142M |
| December 31, 2017 | 0.762M |
| Date | Value |
|---|---|
| September 30, 2017 | 0.235M |
| June 30, 2017 | 0.0529M |
| March 31, 2017 | 0.093M |
| December 31, 2016 | 0.2498M |
| September 30, 2016 | 0.1622M |
| June 30, 2016 | 0.2885M |
| March 31, 2016 | 1.368M |
| December 31, 2015 | 1.085M |
| September 30, 2015 | 2.056M |
| June 30, 2015 | 1.859M |
| March 31, 2015 | 2.256M |
| December 31, 2014 | 2.542M |
| September 30, 2014 | 2.118M |
| June 30, 2014 | 0.7639M |
| March 31, 2014 | -0.0019M |
| December 31, 2013 | 0.0175M |
| September 30, 2013 | 1.134M |
| June 30, 2013 | 1.124M |
| March 31, 2013 | 1.477M |
| December 31, 2012 | 3.934M |
| September 30, 2012 | 1.352M |
| June 30, 2012 | 1.268M |
| March 31, 2012 | 1.240M |
| December 31, 2011 | 0.9868M |
| September 30, 2011 | 0.9121M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.029M
Minimum
Mar 2020
1.821M
Maximum
Sep 2019
0.3857M
Average
0.202M
Median
Sep 2022
Revenue (Quarterly) Benchmarks
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.065M |
| NovaBay Pharmaceuticals Inc | 3.727M |
| Protalix BioTherapeutics Inc | 10.49M |
| Palatin Technologies Inc | 2.034M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -5.589M |
| Total Expenses (Quarterly) | 3.202M |
| EPS Diluted (Quarterly) | -0.09 |
| Enterprise Value | 26.17M |
| Gross Profit Margin (Quarterly) | 65.20% |
| Profit Margin (Quarterly) | -2.74K% |
| Earnings Yield | -61.03% |
| Normalized Earnings Yield | -51.37 |